Twice-daily dosing of ANX1502, Annexon Biosciences’ experimental oral therapy for autoimmune conditions such as cold agglutinin disease (CAD), reached the desired levels in the blood of healthy volunteers who took part in a Phase 1 clinical trial. Taken by mouth as a liquid suspension, ANX1502 was well tolerated,…
Treatment with rituximab led to improvements in biomarkers of red blood cell destruction among people with cold agglutinin disease (CAD), but the improvements often were short-lived and reversible, according to a real-world analysis in the U.S. The therapy, which often is used off-label for the rare autoimmune disease, also…
A single infusion of one of two doses of SAR445088 — Sanofi’s potential successor to Enjaymo (sutimlimab-jome) — was well-tolerated by people with cold agglutinin disease (CAD) in a small Phase 1b clinical trial. The experimental therapy, also known as riliprubart, appeared to work as expected, with…
A free symposium on complement cascade-targeted treatment approaches for cold agglutinin disease (CAD) will be held live and virtually today ahead of the 2023 American Society of Hematology (ASH) meeting taking place in San Diego, California, Dec. 9-12. Announced in a tweet earlier this week, the session titled…
For a man in Japan, cold agglutinin disease (CAD) was complicated by pulmonary thrombosis, which occurs when a blood clot blocks a blood vessel in the lungs, and organizing pneumonia, a rare type of inflammation in the air sacs of the lungs. The man responded well to treatment with…
Among people with cold agglutinin disease (CAD), more than half were found to have a related autoimmune disorder called cryoglobulinemia, which affected symptom presentation but did not appear to affect survival. That’s according to a small study in which 59% of CAD patients tested positive for cryoglobulins, the…
BioCryst is working to develop a new oral therapy for cold agglutinin disease (CAD) that suppresses the immune complement cascade, and expects to have a lead candidate selected by 2025. This and other drug development plans were shared recently by the biotech company in a “R&D Day”…
A bipartisan team of congressional representatives is proposing new legislation that aims to make it easier for people with rare disorders like cold agglutinin disease (CAD) to access treatments that may be beneficial even if they haven’t been formally approved for that indication. The legislation — called the…
A 2-year-old, healthy girl developed a severe, mixed form of autoimmune hemolytic anemia (AIHA) as a result of infection with SARS-CoV-2, the virus that causes COVID-19, a case study reports. While AIHA — a group of rare autoimmune conditions that include cold agglutinin disease (CAD) — secondary to COVID-19…
In people with cold agglutinin disease (CAD), pre-treatment with rituximab and plasma exchange may help limit complications during surgeries where the patient’s body temperature is decreased, a new report illustrates. The case study, “Total arch replacement for an aortic arch aneurysm with cold agglutinin disease after…
Get regular updates to your inbox.